PMID: 3754999Mar 1, 1986Paper

Treatment of disorders of lipid metabolism with the new lipid regulator X50

Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete
W ReuterA Steinicke

Abstract

With the newly developed lipid regulant X 50 = 1-benzyl-3-(1-carboxyl-methylethoxy)-4-methylpyrazol 15 patient with primary hypercholesterolaemia and hypertriglyceridaemia were treated for 3 months. A significant decrease of the serum triglycerides by 47% in all patients and of the total cholesterol by 32% in half the patients (LDL cholesterol decrease 25%) was the result. Altogether an increase of the linoleic acid of 14% and a decrease of the uric acid of 16% were furthermore the result. There were practically no side effects.

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.